Skip to main content

Table 4 Fasting blood glucose and insulin dose

From: Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

 

Baseline (Visit 2)

End of period 1

End of period 2

FBG (before breakfast) in mmol/L, mean ± SD

   

Sequence A

9.24 ± 2.23

6.48 ± 1.66

6.27 ± 1.32

Sequence B

9.50 ± 2.16

6.60 ± 1.82

6.15 ± 1.42

p-value*

 

0.55

0.46

Daily insulin doses in U, mean ± SD

   

Sequence A

0

24.9 ± 20.3

28.7 ± 20.1

Sequence B

0

24.8 ± 15.7

26.0 ± 17.0

p-value*

 

0.96

0.21

Insulin doses by bodyweight in U/kg, mean ± SD

   

Sequence A

0

0.27 ± 0.20

0.31 ± 0.21

Sequence B

0

0.27 ± 0.15

0.28 ± 0.16

p-value*

 

0.88

0.13

  1. Legend: * Unpaired t-test was applied for comparison of treatments in periods; Sequence A: starting with insulin glargine and then switching to NPH insulin; Sequence B: starting with NPH insulin and then switching to insulin glargine